Forex gej yu we
At times forex gaps lead to corrective price action — after a gap, forex prices tend to reverse and fill up the gap. Following the forex gap fill, the price gap mostly changes directions to continue in the direction of the gap.
Fuzzing - Brute Force Vulnerability Discovery (2007).pdf
After all, the forex news that ignited the forex gap in the market is still active. The fading gap happens when the price gap is refilled within the same day. Some forex traders generally stay away from the forex market when there is a forex gap. These traders fear forex gaps as it always leads to slippage , thus affecting the execution of stop and limit orders. Gap up down strategy can be risky and may result in losses. But another crop of traders views forex gap trading simple and profitable.
- citi nri forex rates.
- Classification of Price Gap Forex.
- What is Forex.
- forex eur usd trading hours.
- forex ea reviews 2018.
- О.Магнай жасгаал хийх эрх авчээ?
To them, a gap in the market presents golden opportunities to make money with a fixed stop-loss, a predictable take profit size, and a favourable pattern. To make winning trades, traders have to consider gap levels, and gap filling in their gap up and gap down strategy. Gap up candlestick pattern shows areas of support, whereas the gap down candlestick pattern indicates the resistance level.
Based on the time when the gap occurs, forex gap is divided into the weekly and intraday gap as outlined below:. FX currency trading ends typically on Friday and resumes only on Sunday night. Over the weekend some fundamentals forex news may develop, causing a rapid change in the closing price of a currency pair. Weekly gaps are easily seen on the gap up chart pattern on most timeframes. The gap in forex trading can also happen within a day, though rarely compared to the weekly forex gap.
It usually occurs following a major economic report release or international news of extraordinary events. After such events, forex investors change their forex sentiments and gravitate towards placing new orders at new prices that are higher or lower than the current forex market prices resulting in price breaks. The breakaway gap: this occurs as a trend pattern ends and another one kicks in.
Breakaways are not readily tradable.
Wikipedia:Shortcut table/lowercase
Runaway gap: they typically occur in a price trend. The runaway gaps are safe and easy to trade as traders can easily predict its trend direction. Our failure to implement and maintain effective internal control over financial reporting could result in material misstatements in our financial statements which could require us to restate financial statements, cause investors to lose confidence in our reported financial information and have a negative effect on our stock price.
In the course of having our consolidated financial statements audited for the year ended December 31, and , we and our independent registered public accounting firm identified one material weakness in our internal control over financial reporting as of December 31, In accordance with the standards established by the Public Company Accounting Oversight Board of the United States, a material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.
The material weakness related to the lack of sufficient accounting personnel with U. GAAP knowledge and SEC financial reporting requirements for the purpose of financial reporting, and lack of accounting policies and procedures over financial reporting in accordance with U. During , we implemented a number of measures to remedy this material weakness, including adding staff with extensive U.
GAAP experience to our accounting team and developing, communicating and implementing an accounting policy manual for our financial reporting personnel for recurring transactions and period-end closing processes and improving the capabilities of existing financial reporting personnel through training and education in the accounting and reporting requirements under U.
As of December 31, , based on the measures relating to formal process to identify and address risk of material misstatement related to U. GAAP reporting and other controls implemented as described above, we believe we have been able to remediate the identified material weakness as mentioned above, we believe we have been able to remediate the identified material weakness as mentioned above.
However, we cannot assure you that additional material weaknesses or significant deficiencies in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional significant deficiencies or material weaknesses, cause us to fail to meet our periodic reporting obligations or result in material misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control over financial reporting.
Furthermore, we will be required, pursuant to Section of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting as of the end of our fiscal year ending on December 31, We could be an emerging growth company for up to five years.
The existence of a material weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause us to fail to meet our reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.
In addition to in-licensing or acquiring drug candidates, we may engage in future business acquisitions that could disrupt our business, cause dilution to our ADS holders and harm our financial condition and operating results. While we currently have no specific plans to acquire any other businesses, we have, from time to time, evaluated acquisition opportunities and may, in the future, make acquisitions of, or investments in, companies that we believe have products or capabilities that are a strategic or commercial fit with our current drug candidates and business or otherwise offer opportunities for our company.
In connection with these acquisitions or investments, we may:. We also may be unable to find suitable acquisition candidates and we may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed negatively by customers, financial markets or investors. Further, future acquisitions could also pose numerous additional risks to our operations, including:.
We may not be able to complete one or more acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition without a material adverse effect on our business, financial condition and results of operations. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate any revenue.
We do not currently have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the SDA, FDA and comparable regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services.
What is Gap Forex & What are Gap Trading Strategies - PIPS EDGE
If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.
Reimbursement may not be immediately available for our drug candidates in China, the United States or other countries, which could diminish our sales or affect our profitability. The regulations that govern pricing and reimbursement for pharmaceuticals vary widely from country to country.
Uploaded by
These determinations are made based on a number of factors, including price and efficacy. The NRDL expands its scope by including an additional drugs. The NRDL reflects an emphasis on innovative drugs and drugs that treat cancer and other serious diseases. For instance, most of the innovative chemical drugs and biological products approved in China between and the first half of have been included in the NRDL or its candidate list. Most of our drug candidates targeted at treating oncology diseases, including ZL, are unlikely to be included in the NRDL for the National Medical Insurance Program at least in the short-term.
Products included in the NRDL are typically generic and essential drugs. More recently, the government has started to include more innovative drugs in the NRDL.
As a result, if we were to successfully launch commercial sales of our oncology-based drug candidates, including ZL, our revenue from such sales is largely expected to be self-paid by patients, which may make our drug candidates less desirable. On the other hand, if the Ministry of Human Resources and Social Security of the PRC or any of its local counterparts accepts our application for the inclusion of our drug candidates in the NRDL or provincial or local medical insurance catalogues, which may increase the demand for our drug candidates, our potential revenue from the sales of our drug candidates may still decrease as a result of lower prices we may be required to charge for our drug candidates that are included in the NRDL or provincial or local medical insurance catalogues.
In the United States, federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, health care, which include initiatives to reduce the cost of healthcare. For example, in March , the United States Congress enacted the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act, or the Healthcare Reform Act, which expanded health care coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under government healthcare programs.
Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the Healthcare Reform Act. The Trump administration may also take executive action in the absence of legislative action. For example, in October , the President announced that his administration will withhold the cost-sharing subsidies paid to health insurance exchange plans serving low-income enrollees. Actions by the administration are widely expected to lead to fewer Americans having more comprehensive health insurance compliant with the Healthcare Reform Act, even in the absence of a legislative repeal.
BÀI VIẾT THEO THÁNG
Tax reform legislation was also enacted at the end of that includes provisions that. In a November report, the Congressional Budget Office estimates that the elimination will increase the number of uninsured by 4 million in and 13 million in There have also been efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals.
There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices. Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our product candidates if approved for sale in the United States.
- KenzoFX > – Telegram.
- What is Gap Forex & What are Gap Trading Strategies.
- samba binary option.
- how to become rich through forex.
- options power trader reviews.
- 5 Lý Do Không Nên Giao Dịch Vào Kỳ Nghỉ Lễ?
We cannot, however, predict the ultimate content, timing or effect of any changes to the Healthcare Reform Act or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results. Moreover, eligibility for reimbursement in either China or the United States does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including licensing fees, research, development, manufacture, sale and distribution. Interim U. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services.
Net prices for drugs may be reduced by mandatory discounts or rebates required by U. Third-party payors in the United States often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.
Pharmaceutical companies in China are required to comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our efforts to commercialize our drug candidates.